Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences Stock Forecast

Stock Price Forecast

The 20 analysts with 12-month price forecasts for Neurocrine Biosciences stock have an average target of 168.35, with a low estimate of 114 and a high estimate of 219. The average target predicts an increase of 39.49% from the current stock price of 120.69.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$114	$168.35	$170	$219
Change	-5.54%	+39.49%	+40.86%	+81.46%

Analyst Ratings

The average analyst rating for Neurocrine Biosciences stock from 21 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Sep '24	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25
Strong Buy	8	8	8	6	5	6
Buy	11	11	11	11	11	11
Hold	5	5	5	5	5	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	24	24	24	22	21	21

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Andrew Fein HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $185	Strong Buy	Reiterates	$185	+53.29%	Feb 21, 2025
Yatin Suneja Guggenheim	Guggenheim	Strong Buy Maintains $165 → $163	Strong Buy	Maintains	$165 → $163	+35.06%	Feb 10, 2025
Andrew Fein HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $190 → $185	Strong Buy	Maintains	$190 → $185	+53.29%	Feb 10, 2025
Brian Abrahams RBC Capital	RBC Capital	Hold Maintains $154 → $148	Hold	Maintains	$154 → $148	+22.63%	Feb 7, 2025
Laura Chico Wedbush	Wedbush	Buy Maintains $157 → $147	Buy	Maintains	$157 → $147	+21.80%	Feb 7, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

2.74B

Increased by 16.29%

from 2.36B

Revenue Next Year

3.20B

Increased by 16.90%

from 2.74B

EPS This Year

4.45

Increased by 35.19%

from 3.29

EPS Next Year

6.73

Increased by 51.40%

from 4.45

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	1.05B	1.13B	1.49B	1.89B	2.36B	2.74B	3.20B	3.65B
Revenue Growth	32.71%	8.38%	31.34%	26.76%	24.81%	16.29%	16.90%	14.05%
EPS	4.16	0.92	1.56	2.47	3.29	4.45	6.73	9.13
EPS Growth	966.67%	-77.88%	69.57%	58.33%	33.20%	35.19%	51.40%	35.56%
Forward PE	-	-	-	-	-	27.13	17.92	13.22
No. Analysts	-	-	-	-	-	28	23	19

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	2.9B	3.5B	4.4B
Avg	2.7B	3.2B	3.7B
Low	2.6B	2.9B	3.2B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	22.9%	29.6%	36.9%
Avg	16.3%	16.9%	14.1%
Low	8.9%	6.5%	-0.3%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	6.38	9.64	14.84
Avg	4.45	6.73	9.13
Low	2.79	4.01	3.94

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	93.9%	116.7%	120.3%
Avg	35.2%	51.4%	35.6%
Low	-15.1%	-9.9%	-41.5%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.